How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,334 results for

Myocardial Infarction Stabilization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

3201. SHOCK: Early PCI/CABG in MI + shock

SHOCK: Early PCI/CABG in MI + shock SHOCK - Wiki Journal Club SHOCK From Wiki Journal Club Jump to: , Hochman JS, et al. "Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock". The New England Journal of Medicine . 1999. 341(9):625-634. • • Contents Clinical Question Among patients who developed cardiogenic shock during acute MI, what are the benefits of early revascularization compared to initial medical stabilization on mortality? Bottom Line Compared (...) to initial medical stabilization, early revascularization was associated with a nonsignificant trend towards improved survival at 30 days among patients who developed cardiogenic shock during acute MI. However, early revascularization did confer a significant benefit by 6 months. Major Points The role of primary PCI in cardiogenic shock was evaluated in the 1999 SHould we emergently revascularize Occluded Coronaries for Cardiogenic shocK (SHOCK) trial, which randomized 302 patients in cardiogenic shock

1999 Wiki Journal Club

3202. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology

EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology B. Hesse 1 ,K.Ta ¨gil 2 , A. Cuocolo 3 , C. Anagnostopoulos 4 , M. Bardie ´s 5 , J. Bax 6 , F. Bengel 7 , E. Busemann Sokole 8 , G. Davies 9 , M. Dondi 10 , L. Edenbrandt 2 , P. Franken 11 , A. Kjaer 1 , J. Knuuti 12 , M. Lassmann 13 , M. Ljungberg 14 , C. Marcassa 15 , P. Y. Marie 16 , F. McKiddie 17 , M. O’Connor 18 , E (...) Hospital, London, UK Published online: 21 May 2005 © Springer-Verlag 2005 Abstract. The European procedural guidelines for radio- nuclide imaging of myocardial perfusion and viability are presented in 13 sections covering patient information, radio- pharmaceuticals, injected activities and dosimetry, stress tests, imaging protocols and acquisition, quality control andreconstructionmethods,gatedstudiesandattenuation- scatter compensation, data analysis, reports and image dis- play, and positron emission

2005 European Association of Nuclear Medicine

3203. Systematic review of off-pump coronary artery bypass surgery with the aid of the Octopus Tissue Stabilizer: update and re-appraisal 2001

artery disease were included. Outcomes assessed in the review The outcomes reported were classified as safety and efficacy. The peri-operative safety outcomes were: myocardial infarction, intra-aortic balloon pump required, cerebrovascular accident, mean cross-clamp time, mean coronary artery occlusion time, mean duration of bypass, average blood loss, transfusion, atrial fibrillation, mean duration of ischaemia, inotropic support required, and low cardiac output requiring treatment. The post (...) -operative safety outcomes were: mortality, new onset atrial fibrillation, myocardial infarction, cerebrovascular accident, renal insufficiency or failure, sternal infection, re-intervention for bleeding, transfusion, atrial arrhythmias, low cardiac output syndrome, intra-aortic balloon pump required, inotropic support required, neurological complication, confusion, and the early use of diuretics. The peri-operative efficacy outcomes were: mean operative time, mean intensive care unit stay, mean hospital

2001 DARE.

3204. Due caution using early Beta blockers for acute myocardial infarction Full Text available with Trip Pro

Due caution using early Beta blockers for acute myocardial infarction Due caution using early β-blockers for acute myocardial infarction | Critical Care | Full Text Advertisement Menu Search Search all BMC articles Search Menu Table of Contents , Holt Murray and John A Kellum Critical Care 2007 11 :301 © BioMed Central Ltd 2006 Published: 25 January 2007 Citation Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS. Early intravenous then oral metoprolol in 45,852 patients (...) with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622–1632 [ ]. Background Despite previous randomised trials of early β-blocker therapy in the emergency treatment of myocardial infarction (MI), uncertainty has persisted about the value of adding it to current standard interventions (e.g., aspirin and fibrinolytic therapy), and the balance of potential benefits and hazards is still unclear in high-risk patients. Methods Design and setting Prospective blinded

2007 Critical Care - EBM Journal Club

3205. EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia

. If a patient becomes pregnant or begins breast-feeding during the study, she must be withdrawn immediately. Acute ischemic syndrome defined as acute myocardial infarction [MI] (by enzyme or electrocardiogram [ECG] criteria) or unstable angina within 1 month of entry. Uncontrolled moderate hypertension: sitting blood pressure > 160/95mmHg with measurements recorded on at least 2 occasions (for blood pressure control patients must first be stabilized, preferably with a diuretic, and remain on that dosing (...) EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2005 Clinical Trials

3206. N-terminal pro B-type natriuretic peptide is an independent predictor of postoperative myocardial injury in patients undergoing major vascular surgery. Full Text available with Trip Pro

N-terminal pro B-type natriuretic peptide is an independent predictor of postoperative myocardial injury in patients undergoing major vascular surgery. Myocardial ischemia and infarction after surgery remain leading causes of morbidity and mortality in patients undergoing major vascular surgery. B-type natriuretic peptide has been shown to predict early postoperative cardiac events in patients undergoing major noncardiac surgery. We aimed to determine if N-terminal pro B-type natriuretic (...) peptide (NT-pro-BNP), with its longer half-life and greater plasma stability, can predict postoperative myocardial injury in vascular patients.Recruited were 136 patients undergoing elective surgery for subcritical limb ischemia or abdominal aortic aneurysm (AAA) repair. Plasma NT-pro-BNP was measured preoperatively, and troponin-I was measured immediately after surgery and on postoperative days 1, 2, 3, and 5.Twenty-eight patients (20%) sustained postoperative myocardial injury (troponin-I rise

2008 Journal of Vascular Surgery

3207. Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. Full Text available with Trip Pro

Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. Opening of the mitochondrial permeability transition pore (MPTP) has been shown to contribute to myocardial ischemia/reperfusion injury. We sought to demonstrate that the myocardial protective effect of inhibiting MPTP opening with cyclosporine A (CsA) results in stabilization of mitochondrial morphology and is independent of CsA-induced calcineurin inhibition.Thirty (...) -seven rabbits were divided into three groups: control (n = 15), CsA (MPTP and calcineurin inhibitor, n = 12), or FK506 (calcineurin inhibitor, n = 10). Each group received a 1-hour infusion of either a saline vehicle, 25 mg/kg CsA or 1 mg/kg FK506. All animals underwent 30 minutes of regional ischemia and 3 hours of reperfusion. Myocardial infarct size was determined using Evans blue dye and triphenyltetrazolium chloride. In situ oligo ligation was used to assess apoptotic cell death. Transmission

2008 Annals of Thoracic Surgery

3208. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Full Text available with Trip Pro

Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Hypoxia inducible factor-1 (HIF-1) regulates changes in transcription of key genes such as inducible NO synthase (iNOS) in hypoxic/ischemic environments. In normoxia, HIF-1 activation is controlled by HIF-1alpha-prolyl 4-hydroxylases, which target HIF-1alpha for ubiquitination and proteasomal degradation. We hypothesized that normoxic HIF-1 preservation could (...) attenuate cardiac ischemia/reperfusion injury via a preconditioning effect. HIF-1 preservation was achieved by using small interfering RNA (siRNA) to silence murine HIF-1alpha-prolyl-4 hydroxylase-2 (PHD2). PHD2 siRNA reduced PHD2 mRNA expression 89+/-1.5% (P<0.001) in a time- and concentration-dependent manner in normoxic murine microvascular endothelial cells (EC). PHD2 silencing in normoxic EC stabilized HIF-1alpha protein levels while significantly increasing HIF-1 transcriptional activity and iNOS

2006 Circulation Research

3209. Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction Full Text available with Trip Pro

Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction Article Text

2007 Evidence-Based Medicine

3210. Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

the past 6 months No serious non-healing wound, ulcer, or fracture No clinically significant cardiac disease, defined as any of the following: Congestive heart failure Symptomatic coronary artery disease Unstable angina Cardiac arrhythmias not well controlled with medication Myocardial infarction within the past 12 months No comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for study entry or interfere (...) Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning

2008 Clinical Trials

3211. The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Events (Cardiovascular [CV] Death, Non-fatal Myocardial Infarction [MI] or Non-fatal Stroke) During the Time Period for Follow-up of CV Events [ Time Frame: From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years) ] CV death=death due to a CV cause, which included but was not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism (...) The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2008 Clinical Trials

3212. Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer

on antihypertensive medications) Any prior history of hypertensive crisis or hypertensive encephalopathy New York Heart Association (NYHA) grade II or greater congestive heart failure History of myocardial infarction or unstable angina within 6 months prior to study enrollment History of stroke or transient ischemic attack within 6 months prior to study enrollment Significant vascular disease (e.g., aortic aneurysm, aortic dissection) Symptomatic peripheral vascular disease Evidence of bleeding diathesis (...) Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning

2008 Clinical Trials

3213. Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

it is not life threatening or requires palliative procedures (e.g., endobronchial therapy or radiotherapy) No cardiac disease, including any of the following: NYHA (New York Heart Association) class III-IV congestive heart failure Unstable angina (angina symptoms at rest) New onset angina (began within the past 3 months) Myocardial infarction within the past 6 months No uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg or diastolic BP > 90 mm Hg despite optimal medical management (...) Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2008 Clinical Trials

3214. The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis

Electrocardiogram (ECG) Findings [ Time Frame: Day 1 up to Month 12 ] ECG: investigator assessed test to assess cardiac function. ECG abnormality criteria: any abnormality, arrhythmia, rhythm, conduction, morphology, myocardial infarction, ST segment, T waves and abnormal U waves. Number of Participants With Clinically Significant Treatment-Emergent Holter Monitoring Findings [ Time Frame: Day 1 up to Month 12 ] Holter monitoring recorded heart rhythm. Holter monitoring abnormality criteria: any abnormality (...) disease. Patient has a New York Heart Association (NYHA) Functional Classification ≥ III. Patient has other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic inflammatory diseases). Patient has prior non-amyloid cardiac disease such as: myocardial infarction due to obstructive coronary artery disease, active non-amyloid cardiomyopathy (e.g., symptomatic left ventricular dysfunction from any cause

2008 Clinical Trials

3215. The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy

judgment of the Investigator, are due to reduced liver function or active liver disease. Patient has prior non-amyloid cardiac disease, such as myocardial infarction due to obstructive coronary artery disease, active non-amyloid cardiomyopathy (i.e., symptomatic left ventricular dysfunction from any cause other than amyloid), or symptomatic valvular heart disease that significantly contribute to the patient's underlying cardiac signs or symptoms. Patient has a co-morbidity anticipated to limit survival (...) The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies

2008 Clinical Trials

3216. Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

protein:creatinine ratio < 1.0 at screening ORproteinuria < 2+ by urine dipstick or protein ≤ 1 g by 24-hour urine collection Negative serum pregnancy test Not pregnant or nursing Fertile patients must use effective contraception Active infection requiring parenteral antibiotics Poorly controlled high blood pressure (≥ 150 mm Hg systolic and/or100 mm Hg diastolic) despite treatment NYHA class II-IV congestive heart failure Serious cardiac arrhythmia requiring medication Myocardial infarction or unstable angina (...) Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers

2008 Clinical Trials

3217. Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Did Not Respond to First-Line Therapy With Gemcitabine

to enrollment Peripheral neuropathy equal to or greater than grade 2 Clinical AIDS or known positive HIV serology Evidence of concurrent, clinically evident malignancy, except inactive non-melanoma skin cancer and inactive cervical cancer diagnosed or other cancer for which the patient has been disease-free for five years Unstable angina New York Heart Association (NYHA) Grade II or greater congestive heart failure History of myocardial infarction within 3 months History of stroke within 3 months Major (...) Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Did Not Respond to First-Line Therapy With Gemcitabine Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2008 Clinical Trials

3218. Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

criteria: Congestive heart failure, myocardial infarction, or coronary artery bypass graft within the past 12 months Ongoing severe or unstable angina Unstable arrhythmia requiring medication Sensory neuropathy ≥ grade 2 (according to NCI CTCAE v3.0) Known hypersensitivity to any of the agents used in this study Serious medical or psychiatric illness that, in the opinion of the enrolling investigator, is likely to interfere with study participation PRIOR CONCURRENT THERAPY: No prior systemic therapy (...) Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail

2008 Clinical Trials

3219. Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

or unstable coronary artery disease or has had a myocardial infarction within the last six months Patient with active pulmonary edema or pleural effusion Active infection requiring IV antibiotics Patient currently requires lithium, (due to drug interaction with GM-CSF [Leukine]) Patient currently presents with a neurotoxicity > Grade 1 Women of childbearing potential Patients with a history of other invasive malignancies, within the previous 5 years are excluded, with the exception of non-melanoma skin (...) Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy - Full Text View - ClinicalTrials.gov Hide glossary

2007 Clinical Trials

3220. Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

active infection No uncontrolled hypertension (i.e., blood pressure ≥ 150/100 mm Hg) No uncompensated congestive heart failure or symptomatic coronary artery disease No myocardial infarction within the past 6 months No active bleeding No other invasive malignancies within the past 5 years except for nonmelanoma skin cancer No history of allergic reactions attributed to chemical or biological composition to paclitaxel or other study agents No concurrent amifostine or other protective reagents (...) Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>